<DOC>
	<DOCNO>NCT00419250</DOCNO>
	<brief_summary>The purpose study evaluate safety lenalidomide define maximum tolerated escalation dose level ( MTEDL ) administer stepwise dose-escalation schedule subject relapse refractory B-cell CLL .</brief_summary>
	<brief_title>A Dose Escalation Study Lenalidomide Relapsed Refractory B-cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Documented diagnosis Bcell CLL relapse refractory least one prior regimen . The prior regimen ( ) must include alkylating agent fludarabine ( use combination separately ) ECOG &lt; = 2 Willing agree follow pregnancy precaution . Pregnant nursing woman Systemic treatment Bcell CLL within 28 day study start Central nervous system involvement History renal failure require dialysis Prior treatment lenalidomide Alemtuzumab therapy within 56 day initiate lenalidomide treatment ANC &lt; 1000 / ul Platelet count &lt; 50,000 / ul Calculated creatinine clearance &lt; 60 mL/min ( CockroftGault method ) AST ALT &gt; 3.0 x upper limit normal Serum total bilirubin &gt; 2.0 mg/dl Neuropathy &gt; = Grade 2 Uncontrolled autoimmune hemolytic anemia thrombocytopenia Richter 's transformation ( active )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>fludarabine</keyword>
	<keyword>Revlimid</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>CLL</keyword>
	<keyword>B-cell CLL</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
</DOC>